Two months ago GSK (LSE:GSK) had no approved medicine for lung cancer. Today it has one on the US market, a second awaiting a decision from American regulators and a plan to start more than 20 late-stage trials before the year is out.

The change stems from the FTSE 100 drugmaker's $10.6bn Takeover of Nuvalent, a US developer of targeted cancer drugs, which completed on 15 July 2026. Within a week the Food and Drug Administration had approved the first medicine from the deal. At its second-quarter results in late July, GSK then set out plans to speed up R&D, funded by a large cost-savings programme, in one of the most significant strategic shifts in the group's recent history.

From agreement to approval in six weeks

GSK agreed to buy Nuvalent on 9 June and closed the deal through a tender offer on 15 July. The deal value was $10.6bn, or about £8.0bn, and $9.4bn net of the cash acquired, according to GSK's completion statement.

The deal delivered two late-stage lung cancer medicines, both with FDA Breakthrough Therapy and Orphan Drug designations. Zidesamtinib targets ROS1-positive non-small cell lung cancer, and neladalkib targets ALK-positive disease. A third asset, NVL-330, is in early testing for HER2-altered lung cancer.

The payoff came quickly. On 22 July, the FDA approved zidesamtinib, branded Jideytro, for adults with advanced ROS1-positive non-small cell lung cancer who have already received a ROS1 inhibitor. The drug showed a 44% objective response rate in 117 patients, and a 48% response rate among those with brain metastases.

Inside the R&D acceleration plan

GSK's second-quarter results set out the wider plan. Total sales rose 5% at constant exchange rates to £8.4bn, with Specialty Medicines up 14% to £3.8bn and Vaccines up 8% to £2.3bn. General Medicines fell 9%. Core operating profit rose 7% and core Earnings Per Share climbed 9%, while total earnings per share fell sharply to 10.8p.

The company reaffirmed its full-year guidance for turnover growth of 3% to 5% and core operating profit and core earnings per share growth of 7% to 9%. It declared a second-quarter Dividend of 17p and expects 70p for the full year. It also completed its £2bn share buyback programme.

The headline announcement was on R&D. GSK now expects more than 20 Phase III trial starts in 2026, up from 10 previously guided. It is accelerating seven Assets across 18 indications, and targeting £1.9bn of annual savings by 2029, at a programme cost of £2.4bn, to help fund the push. Chief executive Luke Miels said GSK had delivered "another quarter of strong core results performance".

Why oncology is central to GSK's next chapter

GSK has spent several years reshaping itself after spinning off its consumer health Business into Haleon. The group's growth now relies on specialty medicines, vaccines and HIV, and building a stronger presence in cancer is a key part of the strategy. Oncology sales grew 17% in the second quarter to £0.6bn, but remain small compared with the largest cancer franchises in the industry.

Lung cancer is one of the biggest oncology markets, and targeted therapies for patients with specific genetic mutations are a growing segment. Miels said deal completion "accelerates our entry into lung cancer" and provides a platform for risvutatug rezetecan, GSK's B7-H3-targeted antibody-drug conjugate, which is in Phase III for small-cell lung cancer.

The acceleration plan also reflects the challenge facing the whole industry. Several large drugs across the sector face Patent expiries later this decade, and GSK needs new products to replace lost revenue, including from its HIV Franchise over the longer term. Starting more late-stage trials now increases the chance of launches in time to Fill that gap.

The mix of deal-making and internal acceleration is also a signal about Capital allocation. Rather than rely only on its own laboratories, GSK has shown it is willing to buy late-stage assets that can reach patients quickly, then use its commercial scale to launch them. Among the FTSE 100's two big pharmaceutical groups, that makes GSK's story increasingly about execution: turning a fuller pipeline into sales growth that can offset pressure in older parts of the portfolio.

Risks to the lung cancer bet

Acquisitions of this size carry risk. GSK paid a substantial price for two medicines aimed at relatively small patient groups, and their commercial success is not guaranteed. Existing ROS1 and ALK treatments from rival drugmakers have not reached blockbuster status, and newer rivals are also competing for the same patients.

Running more than 20 Phase III trials is expensive, and late-stage studies can fail. The £2.4bn cost of the savings programme also has to be absorbed before the benefits arrive. Investors will watch whether higher R&D spending squeezes margins, even though the company has reaffirmed guidance.

There are broader pressures too. General Medicines is in decline, US drug pricing policy remains a source of uncertainty for the whole industry, and Vaccine Demand can be affected by changes in public health policy. Shingrix growth slowed to 3% in the second quarter, a reminder that established products cannot carry growth indefinitely.

Catalysts through the end of 2026

The next major milestone is the FDA decision on neladalkib, which has a target action date of 27 November 2026. Approval would give GSK a second lung cancer medicine within months of closing the deal and a presence in the larger ALK-positive market.

GSK's third-quarter results, usually published in late October, will show early sales of Jideytro and any update on guidance, the R&D plan and the savings programme. Investors will also track the pace of Phase III starts, as the company works towards its target of more than 20 this year, along with news from its vaccines pipeline.

Conclusion

GSK (LSE:GSK) has moved quickly to turn the Nuvalent deal into approved medicines, and its R&D acceleration plan signals a more assertive approach to growth. Second-quarter results gave it a solid base, with guidance reaffirmed. However, the success of the strategy depends on commercial uptake in competitive markets, trial outcomes and cost discipline, all of which will take time to judge.